Company intelligence / Profile preview

Vaccinogen Inc.

Baltimore, Maryland, United Statesvaccinogentx.com ↗

Ownership: Public · VGEN
Employees: ~16
Development stage: Phase 3

Overview

Vaccinogen developed OncoVAX, an autologous tumor cell vaccine designed to prevent recurrence of colon cancer after surgery. The therapy showed promising results in previous Phase III trials by reducing recurrence rates in Stage II colon cancer patients. A confirmatory pivotal Phase IIIb trial ("ACTIVE") was planned but the company's financial and operational difficulties halted further progress. Trading of its stock was suspended by the SEC in September 2017 due to delinquent filings, and its European manufacturing subsidiary went bankrupt that year.

Therapeutic areas: Oncology
Modalities: Autologous tumor cell vaccines (Active Specific Immunotherapy/ASI)
Industry: Biotech

Drug pipeline

2 assets

OncoVAX

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships reported; significant investment from The Investment Syndicate led by Anders Halldin

Financials

Market cap: $6.8B
Total revenue: $27.9T

Beyond the preview

Go deeper on Vaccinogen Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaccinogen Inc..

Explore the full profile